ディスレクシア治療市場：タイプ別、薬剤クラス別、流通チャネル別、地域別

世界のディスレクシア治療市場は、2024年には75億9,000万米ドルと推定され、2031年には117億4,000万米ドルに達すると予測され、2024年から2031年までのCAGRは6.4%です。

図.ディスレクシア治療市場シェア（%）、地域別、2024年

ディスレクシアは、読み書きの能力が損なわれる学習障害です。遺伝的要素が強い神経発達障害です。ディスレクシアには、音韻処理、迅速な命名、ワーキングメモリー、処理速度などの障害を含む複数の原因があります。ディスレクシアは、正確で流暢な単語認識が持続的に困難であり、綴りや解読能力も低いです。ディスレクシアは、世界中でおよそ10％から15％の人が罹患しています。適時に診断し、適切な治療と介入を行うことで、ディスレクシアの人は読み、書き、綴りをより成功させるための戦略を学ぶことができます。世界のディスレクシア治療市場は、ディスレクシア患者が読み書き能力を獲得し、症状を管理できるように、評価と治療の選択肢を提供しています。

市場力学：

世界のディスレクシア治療市場の成長は、ディスレクシアに対する認識の高まりと、その原因や管理アプローチに関する調査の増加が牽引しています。調査によると、米国では4,000万人以上がある程度のディスレクシアを抱えているが、適切な介入サービスを受けているのはわずか10%に過ぎないです。ディスレクシア治療の訓練を受けた臨床医や教師が不足していることが、市場の成長を妨げる可能性があります。また、治療や教育プログラムにかかるコストが高いことも、普及を妨げる要因となっています。しかし、早期診断のための先端技術、モバイルアプリ、スキル向上のためのシリアスゲームの開拓は、市場成長の機会となり得る。失読症の遺伝学と神経生物学をよりよく理解することを目的とした大規模疫学研究への投資は、治療成果を改善する可能性があります。

本調査の主な特徴

• 本レポートでは、世界のディスレクシア治療市場を詳細に分析し、2023年を基準年とした予測期間（2024-2031年）の市場規模（10億米ドル）と年間平均成長率（CAGR%）を掲載しています。
• また、さまざまなセグメントにわたる潜在的な収益成長機会を明らかにし、この市場の魅力的な投資提案マトリックスについて解説しています。
• また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競合戦略などに関する主要考察も提供しています。
• 世界の難読症治療市場における主要企業プロファイルを、企業ハイライト、製品ポートフォリオ、主要ハイライト、業績、戦略などのパラメータに基づいて掲載しています。
• 本レポートからの洞察により、マーケティング担当者や企業の経営陣は、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。
• 世界のディスレクシア治療市場は、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界の様々な利害関係者に対応しています。
• 利害関係者は、世界のディスレクシア治療市場の分析に使用される様々な戦略マトリックスを通じて、意思決定を容易にすることができます。

目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場の展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー
• Coherent Opportunity Map（COM）

第3章 市場力学、規制、動向分析

• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• 影響分析
• 市場動向
• 疫学
• 主な発展
• 規制シナリオ
• 買収と提携のシナリオ
• 製品の発売/承認
• 資金調達と投資
• PEST分析
• ポーターの分析

第4章 世界のディスレクシア治療市場- コロナウイルス（COVID-19）パンデミックの影響

• 全体的な影響
• 政府の取り組み
• COVID-19による市場への影響

第5章 世界のディスレクシア治療市場、タイプ別、2019年-2031年

• 音韻失読症
• 表面失読症
• 二重障がいディスレクシア
• その他

第6章 世界のディスレクシア治療市場、薬剤クラス別、2019年-2031年

• 抗ヒスタミン薬
• 中枢神経刺激薬
• 選択的ノルエピネフリン再取り込み阻害剤
• その他

第7章 世界のディスレクシア治療市場、流通チャネル別、2019年-2031年

• 病院薬局
• 小売薬局
• オンライン薬局

第8章 世界のディスレクシア治療市場、地域別、2019年-2031年

第9章 競合情勢

• 企業プロファイル
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Jubilant Pharma Limited
  • GSK plc
  • Eli Lilly and Company
  • Otsuka Holdings Co., Ltd.
  • Apotex Corporation
  • Purdue Pharma
  • Rhodes Pharmaceuticals LP
  • Cian Healthcare Pvt. Ltd.
  • Wallace Pharmaceuticals Ltd.
  • The Himmel Group
  • Astrazeneca
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Lupin

第10章 アナリストの見解

• Wheel of Fortune
• アナリストの見解
• Coherent Opportunity Map

第11章 参考文献と調査手法

• 参考文献
• 調査手法

Global dyslexia treatment market is estimated to be valued at USD 7.59 Bn in 2024 and is expected to reach USD 11.74 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.4% from 2024 to 2031.

Figure. Dyslexia Treatment Market Share (%), By Region, 2024

Dyslexia is a learning disorder that impairs a person's ability to read and write. It is a neurodevelopmental disorder with a strong genetic component. There are multiple causes that contribute to dyslexia including difficulties with phonological processing, rapid naming, working memory and processing speed. It is a persistent difficulty in accurate and fluent word recognition and poor spelling and decoding abilities. Dyslexia affects approximately 10% to 15% of people worldwide. With timely diagnosis and appropriate treatment and intervention, people with dyslexia can learn strategies to read, write and spell much more successfully. Global dyslexia treatment market provides evaluation and treatment options to help dyslexic individuals achieve literacy skills and manage the symptoms.

Market Dynamics:

Global dyslexia treatment market growth is driven by growing awareness about dyslexia and increasing research on its causes and management approaches. According to studies, over 40 million people in the U.S. have some degree of dyslexia, however, only 10% receive appropriate intervention services. The shortage of trained clinicians and teachers for dyslexia treatment can hamper the market growth. High costs of therapies and education programs can also limit adoption. However, the development of advanced technologies for early diagnosis, mobile apps and serious games for skill building can provide opportunities for the market growth. Investments in large epidemiological studies that aim to better understand the genetics and neurobiology of dyslexia can improve treatment outcomes.

Key Features of the Study:

• This report provides an in-depth analysis of the global dyslexia treatment market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global dyslexia treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this includes Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Jubilant Pharma Limited, GSK plc, Eli Lilly and Company, Otsuka Holdings Co., Ltd., Apotex Corporation, Purdue Pharma, Rhodes Pharmaceuticals L.P., Cian Healthcare Pvt. Ltd., Wallace Pharmaceuticals Ltd., The Himmel Group, Astrazeneca, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Lupin
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global dyslexia treatment market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dyslexia treatment market

Detailed Segmentation-

• By Type:
  • Phonological Dyslexia
  • Surface Dyslexia
  • Double Deficit Dyslexia
  • Others
• By Drug Class:
  • Antihistamines
  • Central Nervous Stimulant
  • Selective Norepinephrine Reuptake Inhibitors
  • Others
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Jubilant Pharma Limited
  • GSK plc
  • Eli Lilly and Company
  • Otsuka Holdings Co., Ltd.
  • Apotex Corporation
  • Purdue Pharma
  • Rhodes Pharmaceuticals L.P.
  • Cian Healthcare Pvt. Ltd.
  • Wallace Pharmaceuticals Ltd.
  • The Himmel Group
  • Astrazeneca
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Lupin

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Type
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Epidemiology
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Product Launches/Approvals
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Dyslexia Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Dyslexia Treatment Market, By Type, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Phonological Dyslexia
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Surface Dyslexia
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Double Deficit Dyslexia
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Dyslexia Treatment Market, By Drug Class, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Antihistamines
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Central Nervous Stimulant
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Selective Norepinephrine Reuptake Inhibitors
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Dyslexia Treatment Market, By Distribution Channel, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Dyslexia Treatment Market, By Region, 2019 - 2031, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2031
  • Regional Trends
    • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.S.
    • Canada
    • Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
    • Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profiles
  • Pfizer, Inc.*
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Teva Pharmaceutical Industries Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Jubilant Pharma Limited
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • GSK plc
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Eli Lilly and Company
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Otsuka Holdings Co., Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Apotex Corporation
  • Purdue Pharma
  • Rhodes Pharmaceuticals L.P.
  • Cian Healthcare Pvt. Ltd.
  • Wallace Pharmaceuticals Ltd.
  • The Himmel Group
  • Astrazeneca
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Lupin

10. Analyst View

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact